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Prescription Pattern of NSAIDs and the Prevalence of NSAID-
induced Gastrointestinal Risk Factors of Orthopaedic Patients in 
Clinical Practice in Korea
This is a cross-sectional observational study undertaken to explore the current prescription 
pattern of non-steroidal anti-inflammatory drugs (NSAIDs) and the prevalence of NSAID-
induced gastrointestinal (GI) risk factors of orthopaedic patients in real clinical practice in 
Korea. Study cohort included 3,140 orthopaedic outpatients at 131 hospitals and clinics 
between January 2008 and August 2008. A self-administered questionnaire was completed 
by each patient and physician. A simplified risk scoring scale (the Standardized Calculator 
of Risk for Events; SCORE) was used to measure patients’ risk for GI complications. The 
pattern of NSAIDs prescription was identified from medical recordings. Forty-five percents 
of the patients belonged to high risk or very high risk groups for GI complications. The 
cyclooxygenase-2 enzyme (COX-2) selective NSAID showed a propensity to be prescribed 
more commonly for high/very high GI risk groups, but the rate was still as low as 51%. In 
conclusion, physician’s considerate prescription of NSAIDs with well-understanding of each 
patient’s GI risk factors is strongly encouraged in order to maximize cost effectiveness and 
to prevent serious GI complications in Korea. Other strategic efforts such as medical 
association-led education programs and application of Korean electronic SCORE system to 
hospital order communication system (OCS) should also be accompanied in a way to 
promote physician’s attention.
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ORIGINAL ARTICLE
Musculoskeletal Disorders
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the 
most commonly used medications in the world. NSAID-induced 
adverse reactions involve upper gastrointestinal (GI) tract com-
plications, which can be life-threatening. GI complications oc-
cur in 1%-5% of patients taking NSAIDs for more than one year 
and result in high costs and mortality (1-6). Rates of GI compli-
cations may vary substantially depending on each patient’s clin-
ical characteristics. Identification of the NSAID-related GI risk 
factors is therefore crucial in determining the proper treatment 
for each patient. Many studies already reported that the devel-
opment of serious GI complications are highly correlated with 
certain factors, including health status of disability (7, 8), increas-
ing age (2), concomitant use of systemic steroids (9) or antico-
agulants (10), history of a GI ulcer of bleed (11), diagnosis of 
rheumatoid arthritis (4), certain patterns of prior NSAID use 
(12), history of cardiovascular disease (13), smoking status (7, 
14), and NSAID-related GI symptoms (8, 10, 15).  
 Prior to market release of the first cyclooxygenase-2 enzyme 
(COX-2) selective inhibitor (celecoxib), northern California health 
maintenance organization (HMO) developed a treatment guide-
line for the use of NSAIDs based on the Standardized Calcula-
tor of Risk for Events (SCORE) program developed at Stanford 
University, Division of Immunology and Rheumatology (2, 8). 
The SCORE tool stratifies patients by risk of developing serious 
GI complications using patient characteristics that have assigned 
points. After May 1999, different NSAIDs were recommended 
for patients depending on the total number of points assigned 
by the SCORE tool. 
 It is desirable that physicians consider each patient’s clinical 
factors before prescribing NSAIDs. Some studies already dem-
onstrated the relationship between the clinical factors and the 
use of the NSAIDs (16). However, few domestic studies have 
been undertaken on physician’s prescription patterns of NSAIDs 
and the GI risks factors of the patients taking them. 
 In this study, we evaluated the current prescription pattern of 
NSAIDs and the prevalence of NSAID-induced GI risk factors of 
orthopaedic patients in real clinical practice in Korea. 
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MATERIALS AND METHODS
This was a cross-sectional observational study of Korean patients 
taking NSAIDs for the treatment of orthopaedic problems. 
Study members included 3,140 all adults (20 yr-old or older) 
who visited orthopaedic department of 131 hospitals (9 general 
hospitals, 122 private clinics) in the period between January 
and August 2008. 
 A self-administered questionnaire was prepared to assess the 
risk factors of GI complications. The questionnaire was given to 
the patients at the outpatient office who agreed to complete the 
questionnaire and was filled directly by the patients. The ques-
tions on the risk factors of GI complications consisted of age, 
current health status, smoking habit (over 10 cigarettes/day or 
less), drinking habit (100 g/day), diagnosis of rheumatoid arthri-
tis, history of Helicobactor pylori infection, concomitant use of 
corticosteroids (number of months in a year), long-term NSAIDs 
therapy (≥ 3 months), aspirin use, anticoagulant use, selective 
serotonin reuptake inhibitor (SSRI) use, previous hospitaliza-
tion event due to GI problems (an ulcer or a bleed), history of 
GI symptoms and diagnosis of co-morbid disease (cardiovas-
cular, kidney, liver, diabetes, hypertension). 
 Additionally, we employed GI SCORE for each patient. The 
GI SCORE takes into account six predictors (age, diagnosis of 
rheumatoid arthritis, current health status, proportion of time 
taking steroids, history of a previous GI side effects, and history 
of a previous GI hospitalization) which were already identified 
from the questionnaires (16). A certain number of points were 
allocated for the responses of each predictor and the GI SCORE 
was calculated for each patient. The risk levels were stratified 
into 4 groups. A score of 10 or less indicated that risk of a seri-
ous GI problem was low; 11-15 points indicated moderate risk; 
16-20 points indicated high risk; and more than 20 points indi-
cated very high risk.
 The data on the prescription type of the NSAIDs were filled 
up by the physicians at the outpatient clinic office. The patterns 
of NSAIDs prescription were analyzed and the percentage of 
COX-2 inhibitor prescription was also assessed in each risk group. 
Ethics statement
This study was approved by the institutional review board of Sam-
sung Medical Center, Seoul (IRB No. : 2010-09-041-001). Informed 
consent was exempted by the board.
RESULTS
A total of 3,140 adult patients taking NSAIDs were eligible for 
this study. Women accounted for 69% of the patients and the 
average age for the group was 63.1 (20-98) yr. When dividing into 
two age subgroups, 1,690 (54%) patients were aged over 65 yr 
and females were 75% in the older aged group (≥ 65 yr). Arthri-
tis was the most common cause of taking NSAIDs (67%), fol-
Table 1. List of diagnosis at the time of hospital visit  
Diagnosis
Total  
(n = 3,140)
Hospital type Gender Age (yr)
General hospital
(n = 827)
Private clinic
(n = 2,313)
Male
(n = 952)
Female
(n = 2,173)
< 65
(n = 1,450)
≥ 65
(n = 1,690)
Arthritis 67% 81 62 55 72 56 76
   Knee arthritis 31% 31 30 22 34 25 35
Spinal disease   9%   2 11 11   8   9   9
   Spinal stenosis   5%   1   7   6   5   4   7
   Herniated lumbar disc   2%   1   3   3   2   4   1
Fracture   5%   3   6   9   4   7   4
   Wrist/hand fracture   1%   0   1   1   0   1   0
   Foot/ankle fracture   1%   1   1   2   1   1   1
   Femur fracture   1%   1   0   1   1   0   1
Sprain   4%   0   6   7   3   8   1
   Lumbar sprain   2%   0   2   2   1   3   1
Other inflammatory disease   4%   1   6   6   4   6   3
   Epicondylitis   1%   0   2   2   1   2   0
Other diseases 12% 11 12 15 11 15   9
Table 2. Gastrointestinal (GI) risk factors in the overall study population
GI risk factors Percent of cases (%)
Need for long-term NSAID use 79
Age over 65 yr 54
Comorbid disease (cardiovascular, renal, liver, diabetes,  
   hypertension)
46
High dose of NSAID use 43
History of GI symptom 36
Aspirin use 15
Heavy smoking habit 14
Heavy drinking habit 13
History of steroid use   8
Currently poor health status   8
Rheumatoid arthritis   6
Previous hospitalization history due to GI events   6
Selective serotonin reuptake inhibitor (SSRI) use   4
Helicobactor pylori infection   4
Anticoagulant use   2
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lowed by spinal disease (9%), fracture (5%), sprain (4%), other 
inflammatory disease (4%), and others (12%) (Table 1). 
 Among the GI risk factors identified in the questionnaire, long-
term use of NSAIDs (≥ 3 months) was the most prevalent risk 
factor in the overall study population, followed by old age (≥ 65 
yr) (54%), co-morbid disease (cardiovascular, renal, liver, dia-
betes, hypertension) (46%), higher NSAID doses (43%), previ-
ous GI events (36%) and aspirin use (15%) (Table 2). 
 When the study groups were stratified into four risk groups 
according to GI SCORE tool, 45% of the patients belonged to 
high risk or very high risk groups for GI complications, and fe-
male accounted for about 75% (Fig. 1). Female patients tended 
to be more risky compared to male patients (49% vs 37%), and 
older groups (≥ 65 yr) had greater GI risk compared to younger 
groups (< 65 yr) (72% vs 14%). The proportion of arthritis pa-
tients also had a tendency to be greater as the risk level was high-
er (31% [low risk] < 67% [moderate] < 71% [high] < 76% [very 
high]).  
 When the type of prescription was analyzed in overall study 
groups, celecoxib (COX-2 selective inhibitor) was the most com-
monly used NSAIDs, comprising 36% of the patients. Aceclofe-
nac (22%), meloxicam (15%), zaltoprofen (7%), nabumetone 
(5%), loxoprofen (5%), and talniflumate (5%) were followed con-
secutively (Table 3). 
Pe
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3
34
35
20
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9
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5
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1
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7
7
7
21
0
65
Very high
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5
Fig. 1. Composition of GI risk groups according to 
SCORE tool. 
Table 3. The type of prescription in overall study groups (units in %)
Drugs
Total 
(n=3,140)
Gender Hospital type Age Risk level
Male Female
General 
hospital
Private 
clinic
< 65 yr ≥ 65 yr Low Moderate High Very high
NSAIDs
   Celecoxib 36 28 39 32 37 14 54   6 28 51 56
   Aceclofenac 22 26 21 14 25 28 18 27 25 17 21
   Meloxicam 15 12 16 15 14 18 11 16 16 13 10
   Zaltoprofen   7   8   6 11   6 10   4 10   8   6   4
   Nabumetone   5   6   5   8   4   7   4 10   5   4   3
   Loxoprofen   5   6   4   1   6   6   3   7   4   3   7
   Talniflumate   5   8   4   0   7   9   2 14   6   3   1
   Chondroitin sodium sulfate   0   0   0   0   0   0   0   0   0   0   1
   Clematis mandshurica   1   1   1   0   1   1   0   2   1   0   1
   Dexibuprofen   0   1   0   0   0   0   0   1   0   0   0
   Diacerein   0   0   0   0   0   0   0   0   0   0   0
   Diclofenac   1   1   1   3   0   1   1   1   1  1   1
   Etodolac   2   1   2   6   1   3   1   3   3   1   0
   Glucosamine sulfate   0   0   0   0   0   0   0   0 0   0   1
   Ibuprofen   0   0   0   0   0   0   0   1   0   0   0
   Lornoxicam   0   0   0   1   0   0   0   1   0   0   0
   Morniflumate   1   2   0   1   1   1   0   3   1   0   0
   Naproxen   0   0   0   0   0   0   0   0   0   0   0
   Nimesulid   2   2   1   5   0   3   0   3   2   1   0
   Piroxicam   1   0   1   3   0   0   1   0   1   1   1
   Proglumetacin maleate   0   0   0   0   0   0   0   0   0   0   0
   Sulindac   1   0   1   3   0   1   1   0   1   1   1
   Avocado soya unsafonifiable   0   0   0   0   0   0   0   0   0   0   0
   Ketoprofen   0   0   0   1   0   0   0   0   0   0   1
Opioids
   Ultracet 11 11 12 14 11 11 12   7 11 12 19
Lee S-H, et al. • Prescription Pattern of NSAIDs and the Prevalence of GI Risk Factors of Patients in Korea
564  http://jkms.org DOI: 10.3346/jkms.2011.26.4.561
 COX-2 selective inhibitor was prescribed in 56.2% of very high 
risk patients and 50.9% of high risk patients. Only 51% of patients 
at high or very high risk patients were receiving COX-2 selective 
inhibitors. Analysis of prescription pattern revealed that only 
60% of patients with concomitant anticoagulant use, 54% of the 
patients aged over 65 yr, 52% of patients with concurrent aspirin 
use were prescribed COX-2 selective inhibitor to decrease the 
risk of developing GI complications. Its prescription rate was 
even lower in patients with the other GI risk factors. Comparing 
two age groups with each GI risk factor, its prescription rate was 
greater in older aged groups (≥ 65 yr) overall (Table 4).
DISCUSSION
Multiple case-control population and database studies have 
confirmed that use of NSAIDs increases the risk of significant 
GI complications (e.g., bleeding, hospitalization, surgery) from 
3.5-fold to 7.8-fold overall (4, 17, 18). The adverse events are usu-
ally mild such as in dyspepsia and abdominal pain in most of 
the cases, but sometimes the events can be life-threatening in 
cases of bleeding and perforation. In the United States, it is esti-
mated that approximately 107,000 patients are hospitalized an-
nually for NSAID-related GI complications and at least 16,500 
NSAID-related deaths occur each year among arthritis patients 
alone (15).
 The symptoms of NSAID-induced GI complication vary and 
sometimes can be completely absent, that the understanding 
of the NSAID-induced GI risk factors has been emphasized (19). 
Several epidemiologic studies have identified the risk factors 
for developing GI complications, including health status of dis-
ability (7, 8), increasing age (2), concomitant use of systemic ste-
roids (9) or anticoagulants (10), history of a GI ulcer of bleed (11), 
diagnosis of rheumatoid arthritis (4), certain patterns of prior 
NSAID use (12), history of cardiovascular disease (13), smoking 
status (7, 14), and NSAID-related GI symptoms (8, 10, 15). While 
individual risk factors have been identified by a number of stud-
ies, the necessity of a multivariate risk factor model to permit 
estimation of risk in individual patient and initiation of appro-
priate therapeutic action has been suggested. Fries et al. first 
created a GI bleeding risk model based on Arthritis, Rheuma-
tism, and Aging Medical Information System (ARAMIS) data-
base in 1991 (2). A refined updated model, the SCORE tool, was 
presented in abstract form by Singh et al. in 1998. The SCORE 
tool is accepted as a reliable and accurate predictor of serious 
NSAID-related GI events in rheumatoid arthritis and osteoar-
thritis patients and currently used as a main risk model in relat-
ed studies (16, 20-22).  
  One main purpose of this study was to understand and pres-
ent the NSAID-induced GI risk factors and the actual pattern of 
NSAID prescription in real clinical practice in Korea. Therefore, 
the GI risk factors already identified in previous studies other 
than the SCORE tool have been also included in the question-
naire. This study revealed that long-term use of NSAIDs was the 
most prevalent risk factor in Korean orthopaedic patients, fol-
lowed by old age (over 65 yr) (54%), co-morbid disease (cardio-
vascular, renal, liver, diabetes, hypertension) (46%), use of high 
dose NSAIDs (43%), previous GI events (36%) and aspirin use 
(15%) (Table 2). The Korean Knee Society (KKS) presented com-
parable results, yielding old age over 65 yr (56%), history of pre-
vious GI symptom (40%), presence of co-morbid disease (25%) 
were prevalent risk factors in the NSAID-induced GI risk man-
agement study in 2009 (22). 
 Our study also showed that about half (45% in this study) of 
the population taking NSAIDs for a number of reasons were clas-
sified into high/very high risk groups for GI complications, but 
only 51% of them were given COX-2 selective inhibitor for the 
prevention of GI events. Similarly, only 50% of old patients (over 
65 yr) with previous GI symptom and only 60% of old aged pa-
tients previously hospitalized due to GI events were prescribed 
COX-2 selective inhibitor. Korea Food and Drug Administration 
has forbidden the combined use of non-selective NSAIDs with 
aspirin due to high bleeding tendency and decreased renal func-
tion. Nonetheless, the proportion of the combined use of non-
selective NSAIDs among the patients taking aspirin was high up 
to 48% in our study. Physician’s neglect on patient’s GI factor in 
real practice, each physician’s preference for a specific NSAID, 
vigorous marketing of pharmaceutical companies, harsh cur-
tailment of medical expenses by Health Insurance Review and 
Assessment Service (HIRAS) as well as unawareness of the pa-
tients could be accounted for the inappropriate NSAIDs pre-
scription.
  Although COX-2 selective inhibitor significantly decreases 
Table 4.  Prescription pattern of COX-2 inhibitor according to the GI risk factors
GI risk factors
Selective  
COX-2 inhibitor 
use (units in %)
Age
< 65 yr ≥ 65 yr
Anticoagulant use 60 25 79
Age over 65 yr 54 - 54
Aspirin use 52 26 64
Previous hospitalization history due to  
   GI events
45 19 60
Selective serotonin reuptake inhibitor  
   (SSRI) use
44 24 54
Comorbid disease (cardiovascular, renal, 
   liver, diabetes, hypertension)
44 20 56
History of steroid use 43 20 64
Rheumatoid arthritis 43 28 59
Helicobactor pylori  infection 43 22 58
High dose of NSAID use 40 16 58
Currently poor health status 40 18 49
Need for long-term NSAID use 37 14 55
History of GI symptom 34 15 50
Heavy smoking habit 29 10 54
Heavy drinking habit 27 10 51
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GI complications compared to non-selective NSAIDs, its uncon-
ditional prescription is inappropriate because cost-effectiveness 
of COX-2 selective inhibitor is likely to be lower in population 
at lower risk for GI complications (16). The northern California 
HMO guideline recommended different NSAIDs for patients 
depending on the total number of points assigned by the SOCRE 
tool (16). A COX-2 selective inhibitor was recommended for pa-
tients with a score of 21 or greater; a moderate-risk NSAID such 
as nabumetone, etodolac, or salsalate for patients with interme-
diate scores (16-20 points); and a traditional NSAID such as ibu-
profen, sulindac or naproxen for patients with the lowest scores 
(1-15 points). This treatment guideline was designed to maxi-
mize the cost-effectiveness of NSAID utilization by prescribing 
less expensive non-selective NSAIDs for the patients at low GI 
risk and reserving expensive COX-2 selective inhibitor for the 
patients at higher risk. With an effort such as mailing the guide-
line to the physicians enrolled in the HMO and education pro-
gram through drug education pharmacists, a 5.5-fold difference 
in the use of COX-2 selective NSAIDs was obtained between the 
patients in the highest-risk decile and the patients in the lowest 
risk decile (16). Correspondingly, the risk stratification model 
used in developing the SCORE tool showed that the risk of hos-
pitalization or death due to NSAID-related GI complication de-
creased by approximately 4-fold between arthritis patients in 
higher and lower risk strata (2, 16). Our study resulted in similar 
pattern of NSAID utilization, showing more frequent use of COX-
2 selective inhibitor in higher risk groups (6% [low] < 28% [mod-
erate] < 51% [high] < 56% [very high]) and more common use of 
non-selective NSAIDs in less risk groups. However, it is evident 
that little effort has been made to decrease GI complication for 
Korean patients taking NSAIDs as mentioned before. In an ob-
servational study by Korea Knee Society, only 41% of overall pa-
tients taking NSAIDs and 43% of patients at high risk groups were 
prescribed GI protective medication, indicating that physicians 
make little efforts to consider patient’s individual GI risk factors 
in real practice. Comparable results were reported that the pre-
scription rates of GI protector in patients with current GI symp-
tom and in patients without it were not significantly different 
(44% vs 39%) (22), meaning that physicians prescribe GI protec-
tor rather in the customary manner without considering patient’s 
factor. Physician’s voluntary efforts to put more attention on in-
dividual factor, patient’s self-awareness on the adverse effects 
caused by NSAIDs as well as government-led promotion pro-
grams such as mailing guideline booklets and periodic educa-
tion program could aid in decreasing GI complications induced 
by NSAIDs medication. 
 Cote et al. (23) reported that after the intervention (combina-
tion of education and computer alert), the use of gastroprotec-
tor in high risk patients increased from 45% with no interven-
tion to 52% with physician education alone, to 46% with the com-
puter alert alone, and to 67% with the combination of physician 
education and computer alert (P < 0.005). Recently, a revised 
SCORE tool (electronic SCORE) was designed with an effort to 
easily access patient criteria and estimate a patient’s risk using 
computer-stored medical and demographic information (21). 
Application of electronic SCORE to hospital Order-Communi-
cation system (OCS) could be another method to easily predict 
individual’s risk for NSAID-induced GI complication. 
 This study has a few limitations. First, there were no research-
es on the pattern and type of gastroprotector use. As mentioned 
previously, Korean Knee Society reported the overall prescrip-
tion rate of gastroprotector was as low as 41% and physicians 
used gastroprotector in customary manner rather than consid-
ering patient’s individual factor including current GI symptom 
(22). Young medical specialists (with certification year less than 
10) prescribed gastroprotectors more actively, assuming that 
doctors recently educated were rather well aware of the severity 
of adverse effects caused by NSAIDs. The most commonly used 
gastroprotector was cytoprotectant followed by H2 receptor an-
tagonist, gastroprokinetic and proton pump inhibitor (22). The 
low prescription rate of proton pump inhibitor seemed to be 
related to low rate of reimbursement by National Health Insur-
ance (NHI). Secondly, this study was a cross-sectional observa-
tional study designed to obtain an initial data for the current pat-
tern of NSAIDs utilization and confirm the prevalence of GI risk 
factors of Korean patients taking NSAIDs. Therefore, we did not 
put much effort to develop new GI risk factor. More interesting 
data could be obtained if we had progressed more research on 
the topic such as new GI risk factor typical to Korean population, 
degree of patient’s awareness on adverse effects by NSAIDs, phy-
sician’s criterion or principle in choosing the type of NSAIDs or 
gastroprotectors. This study is still meaningful in that it offered 
valuable data on the current prescription pattern of NSAIDs in 
real clinical practice in Korea at the very first, and gave us a mo-
ment to share insights on the solution to minimize NSAID-in-
duced GI complications effectively. Strategic efforts such as phy-
sician’s voluntary attention to estimate individual patient’s risk 
factor, patient’s self-awareness on the adverse effects caused by 
NSAIDs, government-led campaign activities such as mailing 
guideline booklets, medical association-led periodic education 
programs for physicians and patients, and development and 
application of Korean electronic SCORE system to hospital Or-
der Communication System (OCS) could aid in decreasing GI 
complications induced by NSAIDs medication.
 In conclusion, although about half of Korean orthopaedic 
patients receiving NSAIDs are at high or very high risk for 
NSAID-induced GI complications, physicians’ prescription pat-
tern for NSAIDs appears to be inconsiderate. Physician’s con-
siderate prescription of NSAIDs with well-understanding of each 
patient’s GI risk factors is strongly encouraged in order to maxi-
mize cost effectiveness as well as to prevent serious GI compli-
cations in Korea. Other strategic efforts such as patient’s self-
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awareness, government-led educational campaigns, medical 
association-led educational programs, and application of Kore-
an electronic SCORE system to hospital OCS should also be ac-
companied in a way to promote physician’s attention.
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This cross-sectional observation study was aimed to explore the current prescription pattern of non-steroidal anti-inflammatory 
drugs (NSAIDs) and the prevalence of NSAID-induced GI risk factors in orthopedic patients (3140 orthopedic outpatients at 131 
hospitals in Korea). Questionnaires and medical recordings showed that 45% of the patients belong to high risk or very high risk 
groups for GI complications. However, only 51% of risked patients were prescribed for COX-2 selective NSAID. Physician’s 
considerate prescription of NSAIDs with well-understanding of each patient’s GI risk factors is strongly requested in Korea. 
